

<b>Interview Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	09/763,978	SALCEDA ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Larry R. Helms	1642	

All participants (applicant, applicant's representative, PTO personnel):

- (1) Larry R. Helms. (3)\_\_\_\_\_.
- (2) Ms. Tyrrell. (4)\_\_\_\_\_.

Date of Interview: 30 September 2004.

Type: a) ☒ Telephonic b) ☐ Video Conference  
c) ☐ Personal [copy given to: 1) ☐ applicant 2) ☒ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☒ No.  
If Yes, brief description: \_\_\_\_\_.

Claim(s) discussed: elected claims for SEQ ID NO:1.

Identification of prior art discussed: none.

Agreement with respect to the claims f) ☐ was reached. g) ☒ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

\_\_\_\_\_  
Examiner's signature, if required

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Advised Ms. Tyrrell that the examiner would rejoin sequences 10-13 with SEQ ID NO:1 wherein the specification teaches SEQ ID NO:10-13 are part of SEQ ID NO:1. In addition advised Ms. Tyrrell that if she could tell the examiner what amino acid sequence SEQ ID NO:1 encodes the examiner would examine the method to the extent the detection is either by the polypeptide or the nucleic acid. Ms Tyrrell advised the examiner that the amino acid encoded by SEQ ID NO:1 is not disclosed in the specification. The Examiner advised Ms. Tyrrell that the examiner would examine claims 1-8 in part reading on the CSG as SEQ ID NO:1, 10-13 and detection was with the nucleic acid. Ms Tyrrell advised the examiner that a new response and claims would be forthcoming.